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Background: Schizophrenia is associated with increased cardiovascular morbidity and mortality. Asymmetric
dimethylarginine (ADMA), an endogenous inhibitor of the nitric oxide synthase, and the L-arginine:ADMA ratio are
markers of endothelial dysfunction that predict mortality and adverse outcome in a range of cardiovascular disorders.
Increased ADMA levels may also lead to increased oxidative stress. We hypothesized that ADMA and the L-arginine:
ADMA ratio are increased in somatically healthy schizophrenia patients treated with atypical antipsychotics (AAP), and
that the ADMA and the L-arginine: ADMA ratio are positively correlated to measures of oxidative stress.
Methods: We included 40 schizophrenia patients treated with AAP, but without somatic disease or drug abuse,
and 40 healthy controls. Plasma concentrations of ADMA and L-arginine were determined by high-performance
liquid chromatography. Data were related to markers of systemic oxidative stress on DNA, RNA and lipids, as well
as measures of medication load, duration of disease and current symptomatology.
Results: Plasma ADMA and the L-arginine:ADMA ratio did not differ between schizophrenia patients and controls.
Furthermore, ADMA and the L-arginine:ADMA ratio showed no correlations with oxidative stress markers, medication
load, or Positive and Negative Syndrome Scale scores.
Conclusions: Schizophrenia and treatment with AAP was not associated with increased levels of plasma ADMA or the
L-arginine:ADMA ratio. Furthermore, plasma levels of ADMA were not associated with levels of systemic oxidative stress
in vivo.
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Schizophrenia is associated with increased somatic mor-
bidity and mortality, primarily due to cardiovascular
disorders [1-4]. The causes for this association are
thought to be poor somatic care, unhealthy lifestyle, and
the side-effects of the most frequently used antipsychotic
agents, known as atypical antipsychotics (AAP), which
may cause weight gain and metabolic syndrome [1].
Collectively, these factors likely converge on the induction
of pathophysiological pathways in the cardiovascular* Correspondence: anders.01.joergensen@regionh.dk
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stated.system that underlies the development of clinical car-
diovascular disease in general, such as endothelial dys-
function [5]. In a recent study of schizophrenia patients
treated mainly with AAP, 48 percent of the study
population (N = 203) were found to meet the criteria
for endothelial dysfunction, as measured by peripheral
artery tonometry [6]. Hence, endothelial dysfunction is a
possible cellular phenomenon underlying the association
between schizophrenia, AAP use, and cardiovascular
mortality.
Nitric oxide (NO) is the main paracrine signaling
molecule in the endothelial regulation of vascular smooth
muscle relaxation. Three isoforms of NO-synthase catalyze
the reaction arginine +O2 - >NO+ citrulline. In conditions
of arginine shortage (as well as other cofactors), thetral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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moting oxidative stress [7]. As an endogenous inhibitor of
the endothelial NO-synthase (eNOS), asymmetric dimethy-
larginine (ADMA) exerts its effects through a reduction in
NO levels. However, increased ADMA levels have also
been associated with increased oxidative stress [8-11].
ADMA administration has been shown to increase levels
of reactive oxygen species in both rodent and human vas-
culature [9,12]. A shift from a NO-mediated quiescent
state of the endothelium to a ROS-mediated activated and
pro-inflammatory state is thought to be a key event in the
transition to atherosclerosis [5].
ADMA and the L-arginine:ADMA ratio has been
shown to predict mortality and adverse outcome in a
range of cardiovascular disorders [5,13-16]. Both preclin-
ical and clinical studies have shown that ADMA has a
pathophysiological role in the induction of vascular
dysfunction and human cardiovascular disease [11]. The
L-arginine:ADMA ratio has been viewed by some au-
thors to be a superior marker for endothelial dysfunc-
tion, as it may reflect the intracellular balance between
substrate and inhibitor of NO-synthesis [17].
Plasma ADMA levels has been investigated in three pre-
vious studies of schizophrenia patients. Das et al. found
that plasma ADMA were elevated in drug-naïve, first epi-
sode patients (N = 16) compared with controls (N = 12)
[18]. Celik et al. found that plasma ADMA levels were in-
creased in both first-episode (N = 24) and multiple episode
(N = 25) schizophrenia patients compared with healthy
controls (N = 30). ADMA was not correlated to symptom-
atology, but was higher in multiple versus first-episode
patients [19]. Zincir et al. found that plasma ADMA
was 3-fold higher in somatically healthy first episode-
schizophrenia patients (N = 49) compared to healthy
controls (N = 30), with a 50% reduction of plasma ADMA
in the patient group after two months of treatment [20].
The purpose of the present study was to determine
plasma levels of ADMA and the L-arginine:ADMA ratio in
somatically healthy schizophrenia patients in treatment
with AAP and healthy controls, and to compare these levels
with measures of systemic oxidative stress on DNA, RNA
and lipids, as well as duration of disease and symptom se-
verity. We hypothesized that ADMA and the L-arginine:
ADMA ratio are increased in schizophrenia; that the
ADMA and the L-arginine:ADMA ratio are positively cor-
related to measures of oxidative stress in both healthy con-
trols and schizophrenia patients; and finally that ADMA
and the L-arginine:ADMA ratio are correlated to duration
of disease, rather than to current symptom severity.
Methods
General study outline
Patients were recruited by referral from doctors at the
Psychiatric Centre Copenhagen, which provides mentalhealth services to the citizens of the central, northern
and north-western area of Copenhagen. Inpatients and
patients from the affiliated outpatient clinics were eli-
gible for inclusion.
The inclusion criterion for patients was an ICD-10
diagnosis of schizophrenia (F20.0-F20.9) confirmed by a
structured interview at referral (see below). Exclusion
criteria were: 1) Somatic disease and somatic medica-
tion. A non-regular use of e.g. painkillers or asthma
medication was allowed, 2) Abuse of alcohol, marihuana
or other drugs of abuse, 3) Coercion of any kind, 4)
Severely disorganised thinking, making it impossible to
obtain an informed consent, 5) Use of dietary supple-
ments, and 6) Pregnancy or breast-feeding. Of forty-five
patients referred to the study and accepting to partici-
pate, 40 were included. In the rejected patients, the diag-
nosis of schizophrenia was considered uncertain after the
inclusion interview (N = 4), or the biochemical screening
revealed a medical disorder (N = 1).
Healthy controls were recruited from the blood dona-
tion corps at Rigshospitalet by personal contact, as they
were scheduled for donating blood. Exclusion criteria for
the healthy controls were: 1) Any psychiatric or somatic
disease, 2) abuse of alcohol, marihuana or other drugs,
3) use of any medication including dietary supplements,
and 4) first degree family members with psychiatric
disease. A total of 175 healthy controls meeting none of
the exclusion criteria were asked to participate, and of
these, 40 accepted to be included.
In all participants, a Schedules in Clinical Neuropsych-
iatry (SCAN)-interview [21] was applied to ensure that
the ICD-10 diagnostic criteria for schizophrenia were
met in patients, and that no lifetime psychiatric morbid-
ity was present in the healthy controls. The severity of
psychopathology was measured (patients only) with the
Positive and Negative Syndrome Scale (PANSS) [22].
The level of perceived stress was assessed with the Per-
ceived Stress Scale 10-item (PSS) [23]. The degree of
childhood adversity were estimated by the Childhood
Abuse and Trauma Scale (CATS) [24]. Exercise levels
(hours per week) were recorded. Exercise was defined as
rigorous physical activity such as running, aerobics,
sports etc.; e.g. “walking to work” or “moving a lot dur-
ing the day” were not recorded as exercise. In patients,
duration of disease, number of psychiatric admissions,
and current psychopharmacological treatment were re-
corded. All patients had received a clinical examination
and regular ECG’s, following the standard protocol of
the department, with no indication of unrecognized
somatic disease.
All participants had blood drawn in the fasting state at
9 a.m. Plasma was obtained from cooled EDTA-coated
tubes which were centrifuged at 4°C and 1590 × g for
10 min. Samples were stored for later analyses at −80°C
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was obtained from the first voided urine after blood
sampling. Urine samples were kept on ice and trans-
ferred within hours to storage at −20°C until analysis.
To screen for unrecognized medical disorders and assess
the cardiovascular risk profile, general biochemical tests
were performed, comprising a full blood count, hepatic
enzymes, total cholesterol, low-density lipoprotein
(LDL) and high-density lipoprotein (HDL) cholesterol,
triglycerides, c-reactive protein (CRP), thyroid stimu-
lating hormone (TSH), sodium, potassium, creatinine,
glucose, glycated hemoglobin (HbA1c), and plasma cor-
tisol. Resting blood pressure and pulse, body weight and
waist-hip ratio were recorded. The presence of meta-
bolic syndrome was identified using criteria from the
American Heart Association/National Heart, Lung, and
Blood Institute [25].
Plasma ADMA and L-arginine determination
Plasma ADMA and L-arginine was determined by High-
Performance Liquid Chromatography as previously de-
scribed [26,27]. Plasma samples underwent solid-phase
extraction (Oasis MCX column, Waters) followed by
high-performance liquid chromatography separation on
a symmetry C18 column, 3.9 Å ~ 15 mm, 5 μm pore
(Waters, WAT046980). The high-performance liquid
chromatography equipment consisted of a Waters 717
plus autosampler, 2Shimadzu LC-20 AD Prominence
Pumps, a Shimadzu DGU-20A5 Prominence Degasser,
and a Shimadzu RF-20A Prominence Fluorescence
Detector. Data collection, peak identification, and calcu-
lation of area under the curve were performed with
Empower 2.0 software (Waters). Standards were pur-
chased from Sigma-Aldrich except for monoethyl arginine
(Enzo Life Sciences).
Oxidative stress marker determination
The urinary content of the oxidatively modified guan-
ine nucleosides 8-oxo-7,8-dihydro-2′-deoxyguanosine
(8-oxodG, a marker of systemic DNA damage from
oxidation) and 8-oxo-7,8-dihydroguanosine (8-oxoGuo, a
marker of systemic RNA damage from oxidation) were
assayed using ultraperformance liquid chromatography
and tandem mass spectrometry (UPLC MS/MS), as pre-
viously described [28]. The 8-oxodG/8-oxoGuo excre-
tion is defined as the urinary concentration of the
nucleoside normalized to urinary creatinine concentra-
tion [29]. Plasma malondialdehyde (MDA, a marker of
lipid peroxidation) was measured, also using previously
described chromatographic methods [30].
Statistics
All data are presented as means ± SD or median (inter-
quartile range). Data were compared with independentsamples t-test, Mann–Whitney test or Chi-squared test,
as appropriate. Correlation analyses were performed by
Spearman or Pearson tests, as appropriate. All correl-
ation analyses were performed in the patient and control
groups separately, as well as in the full study population.
8-oxodG/8-oxoGuo deviated from normal distribution
and were transformed by the natural logarithm before
analyses. All statistical analyses were performed using
the Statistical Package for the Social Sciences (SPSS)
software version 20.0 (IBM Corporation, NY, USA). Stat-
istical significance was defined as p < 0.05. All statistical
tests were two sided.
Ethics
The study protocol complied with the Declaration of
Helsinki, and was approved by the Committee on Research
Ethics of the Capital Region of Denmark (H-D-2008-064)
and the National Data Protection Agency of Denmark
(2008-41-2052). Before inclusion, all participants were
thoroughly informed on the study both in writing and
orally, and all patients were offered to have a healthy
relative present when the information was given. Patients
with severely disorganised thinking, making it impossible
to obtain an informed consent, were not invited for
participation. All participants gave a written informed
consent before inclusion.
Results
Baseline demographic and biochemical characteristics of
the cohort are summarized in Table 1. Disease course
and treatment data for the schizophrenia patients are
summarized in Table 2. Note that these data have been
published previously [31]. All patients received AAPs.
The primary antipsychotic agents used were risperidone
(N = 9), quetiapine (N = 9), aripiprazole (N = 6), olanza-
pine (N = 5), clozapine (N = 5), sertindole (N = 3), zipra-
sidone (N = 2), and amisulprid (N = 1).
We found no differences in ADMA (p = 0.80), L-arginine
(p = 0.80), or the L-arginine:ADMA ratio (p = 0.96) in
schizophrenia patients versus healthy controls (Figure 1).
The absolute values found were: ADMA, schizophrenia:
0.37 ± 0.08 μmol/L, controls: 0.37 ± 0.08 μmol/L; L-arginine,
schizophrenia: 126 ± 22 μmol/L, controls: 128 ± 37 μmol/L;
L-arginine:ADMA ratio, schizophrenia: 354 ± 79, controls:
353 ± 104. The 95%-confidence interval for the differ-
ence in ADMA was −0.04 to 0.03 μmol/L and −40 to 42
for the arginine:ADMA ratio. No significant differences
were found when analyzing males and females separ-
ately (results not presented).
Next, we analyzed correlations between ADMA, the
L-arginine:ADMA ratio and markers of oxidative stress
(8-oxodG, 8-oxoGuo and MDA) in the full study popu-
lation, as well as in the control and schizophrenia
patient group separately. Results are summarized in
Table 1 Basic data of healthy controls and schizophrenia patients
Control (N = 40) Schizophrenia (N = 40) P-value
Gender (M/F) 20/20 20/20 1.0
Age (years) 31.4 ± 9.8 33.0 ± 10.7 0.49
Smoker (%) 21 55 0.002
Cigarettes per day (if smoker) 8.1 ± 6.4 18.1 ± 11.3 0.03
Alcohol (drinks per week) 5 (2–10) 1 (0–5) 0.002
Exercise (hours per week) 3 (1–5) 0 (0–2) <0.001
Body Mass Index 25.1 ± 3.8 27.2 ± 5.7 0.06
Waist-hip ratio 0.80 ± 0.07 0.89 ± 0.08 <0.001
Systolic blood pressure (mmHg) 124.6 ± 11.6 127.1 ± 12.2 0.34
Diastolic blood pressure (mmHg) 78.9 ± 8.6 78.5 ± 7.3 0.37
Pulse (min−1) 64.6 ± 10.6 81.0 ± 14.3 <0.001
Metabolic Syndrome (y/n)a 2/37 11/27 <0.001
Perceived Stress Scale score 7.7 ± 4.2 22.3 ± 6.7 <0.001
Childhood Abuse and Trauma Scale score 11 (8–20) 39 (17–67) <0.001
Total cholesterol (mmol/L) 4.7 ± 0.8 4.9 ± 0.9 0.44
HDL cholesterol (mmol/L) 1.5 ± 0.4 1.4 ± 0.4 0.40
LDL cholesterol (mmol/L) 2.8 ± 0.6 2.8 ± 0.8 0.75
Triglycerides (mmol/L) 0.90 (0.70-1.15) 1.25 (0.76-2.00) 0.02
Glucose (mmol/L) 5.2 ± 0.4 5.1 ± 0.6 0.48
HbA1c (mmol/L) 5.2 ± 0.3 5.4 ± 0.4 0.01
Plasma Creatinine (μmol/L) 73 ± 16 69 ± 14 0.20
CRP (mg/L) 1 (1–2) 2 (1–4) 0.002
Numbers are means ± standard deviation or medians (interquartile range). Data are analyzed with t-tests, Mann Whitney tests or Chi-squared tests, as appropriate.
aAs defined in [25] (because of a few participants with missing values, the sum does not reach 40 in each group). Abbreviations: HDL High-density lipoprotein; LDL
Low-density lipoprotein, HbA1c Glycated hemoglobin. CRP: C-reactive protein.
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the ADMA and oxidative stress markers (Table 3).
There were no significant differences in ADMA or the
L-arginine:ADMA ratio in metabolic syndrome versus
non-metabolic syndrome individuals, neither in the the
schizophrenia patients, the healthy controls, or when
analyzing the population as a whole. Furthermore, we
found no significant correlations between levels of exer-
cise (hours per week) and ADMA or the L-arginine/
ADMA ratio in patients or controls, respectively (results
not presented).
Because psychological stress and childhood adversity
has been linked to cardiovascular disease [32,33], we fur-
ther analyzed correlations between ADMA, the L-arginine:
ADMA ratio, PSS and CATS scores in the full study popu-
lation as well as in the control and schizophrenia patient
group separately. We found no significant associations
between the ADMA markers and measures of subjective
current psychological stress or adverse childhood expe-
riences (results not presented).
Finally, in patients only, we analyzed the correlations
between ADMA, the L-arginine:ADMA ratio, and mea-
sures of current psychopathology, duration of disease,number of lifetime admissions, AAP doses, and duration
of AAP treatment (Table 4). We found a trend towards a
positive correlation between the L-arginine:ADMA ratio
and duration of disease (p = 0.066) as well as number of
lifetime admissions (p = 0.052). Otherwise, there were no
significant associations between ADMA or the L-arginine:
ADMA ratio and measures of current psychopathology
and disease course. Specifically, none of the markers
showed associations to present and past AAP use.
Discussion
This study suggests that schizophrenia patients treated
with AAPs do not have alterations in ADMA and the
L-arginine:ADMA ratio. The lack of association could
perhaps be explained by the fact that the patients inves-
tigated in the present study were on average relatively
young, and participants were excluded if they had any
manifest somatic illness. Many of the schizophrenia
patients did, however, exhibit a mild cardiovascular risk
profile, with more patients than controls having dyslipid-
emia, central obesity, fulfilling criteria for the metabolic
syndrome, etc. The prevalence of the metabolic syn-
drome was even slighty higher than the one found in a
Table 2 Clinical characteristics of the schizophrenia








Age of onset (years) 23.0 ± 5.3
Duration of illness (months) 76 (36–189)
Number of admissions 3 (1–6)
In-patient at inclusion 60%
Medicationa
Duration of current antipsychotic treatment (months) 20 (3–68)
Number of antipsychotics used
One 77%
Two or three 23%
Antipsychotics, Defined Daily Doseb 1.5 (0.7–2.3)
Antidepressant use 43%
If antidepressant use, Defined Daily Dose 1.4 (1.0–2.0)
Benzodiazepine use 28%
If benzodiazepine use, Defined Daily Dose 0.6 (0.3–1.2)
Psychopathology
PANSS positive score 22.2 ± 4.3
PANSS negative score 22.3 ± 5.6
PANSS general score 44.6 ± 8.5
PANSS total score 89.1 ± 16.5
aAll patients received second-generation antipsychotics. Apart from the listed
medications, three patients received anticholinergic agents, two patients
received antiepileptics and one patient received electroconvulsive therapy. bAs
defined by the World Health Organization.
Figure 1 Asymmetric dimethyl arginine (ADMA) and L-arginine:
ADMA ratio in healthy controls and schizophrenia patients.
Data are presented with box plots representing the 1st, 2nd and 3rd
quartiales, whiskers extend the box range times 1.5 or the most extreme
point. The group means are not significantly different with the students
t-test (A: p = 0.8; B: p = 0.96).
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ing that we were unable to identify any differences in
ADMA, which has previously been associated with a
cardiovascular risk profile [5]. Due to the complete
absence of borderline significant trends, it is not likely
that the findings are due to the medium size of the
study, i.e. due to a type II error. The 95% confidence
limits for the difference in plasma ADMA were −0.04-
0.03 μmol/L, implying that any potential difference that
we may have overlooked is likely to be within this range,
which must be considered to be clinically unimportant.
As an endogenous inhibitor of the nitric oxide synthases,
ADMA is a mediator of endothelial dysfunction with
modest correlation to peripheral tonometry [26], and
low correlation to flow mediated dilation [35]) which
are measures of endothelial dysfunction. Thus, it is
possible that some degree of endothelial dysfunction have
been overlooked in the present population. However,ADMA is near the end in a chain of molecular events
leading to endothelial dysfunction, and we therefore
speculate that endothelial dysfunction occurs in associ-
ation to more manifest cardiovascular risk or disease
states than the ones present in our patient population.
The finding is in contrast with the findings of Das
et al., Celik et al. and Zincir et al. [18-20], who found
that ADMA was increased in schizophrenia patients.
These studies also used HPLC to measure ADMA. In
the study by Celik et al., first episode and multiple
episode patients were either drug-naïve or had not re-
ceived antipsychotics at least 3 months prior to blood
sampling [19]. Das et al. found a reduction in ADMA
after the initiation of neuroleptic treatment in a sub-
sample of their drug-naïve patients [18]. Zincir et al.
found a 50% reduction of plasma ADMA in first episode-
schizophrenia patients after two months of treatment [20].
Table 3 Correlations between ADMA, L-arginine:ADMA ratios, and markers of oxidatively generated DNA (8-oxodG),
RNA (8-oxoGuo) and lipid (MDA) damage in all participants, healthy controls, and schizophrenia patients
8-oxodG 8-oxoGuo MDA
All participants
ADMA −0.08 (−0.30 to 0.14) 0.01 (−0.21 to 0.22) −0.109 (−0.33 to 0.12)
L-arginine:ADMA ratio 0.07 (−0.16 to 0.28) −0.02 (−0.24 to 0.20) 0.07 (−0.17 to 0.29)
Healthy controls
ADMA −0.11 (−0.41 to 0.21) −0.11 (0.41 to 0.20) −0.19 (−0.49 to 0.14)
L-arginine:ADMA ratio −0.07 (−0.38 to 0.24) −0.08 (−0.38 to 0.24) 0.12 (−0.22 to 0.43)
Schizophrenia patients
ADMA −0.09 (−0.39 to 0.23) 0.08 (−0.24 to 0.38) −0.06 (−0.37 to 0.26)
L-arginine:ADMA ratio 0.16 (−0.16 to 0.45) 0.02 (−0.29 to 0.33) 0.04 (−0.28 to 0.35)
Data are presented as Pearson correlation coefficients and corresponding 95% confidence intervals. Abbreviations: ADMA Asymmetric dimethyl arginine 8-oxodG
8-oxo-7,8-dihydro-2′-deoxyguanosine, 8-oxoGuo 8-oxo-7,8-dihydroguanosine MDA Malondialdehyde.
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offers a short-term protection against endothelial dysfunc-
tion, perhaps by reducing acute agitation and autonomic
activation. However, we did not find any significant corre-
lations with the objective or subjective clinical severity of
disease, contradicting such a hypothesis. Likewise, we
found a trend towards higher levels of the L-arginine:
ADMA ratio in patients with longer disease duration and
a higher number of psychiatric admissions, i.e. in the
opposite direction of what would be expected if the cumu-
lative load of disease negatively influenced endothelial
function. Finally, the AAP dose or duration of AAP use
were not correlated to the ADMA markers, indicating that
the degree of exposure to AAPs does not influence
ADMA levels. Of note, in the studies by Celic et al. and
Zincir et al., the reported levels af ADMA were appro-
ximately x 10 higher than the ones found in our study,
suggesting that the detected substances are not identical.
The levels found in our study are in line with the reference
ranges suggested by others [36-38].
In the same cohort, we have previously established
substantial differences in markers of systemic oxidative
stress between patients and controls [31]. In this study, we
found no significant correlations between ADMA or ar-
ginine:ADMA and three markers of systemic oxidativelyTable 4 Correlations between measures of current psychopat
patients
ADMA
PANSS score 0.16 (−0.16 to 0.4
Duration of disease −0.04 (−0.34 to 0
Lifetime admissions −0.06 (−0.37 to 0
Defined Daily Dose of AAP 0.17 (−0.15 to 0.4
Duration of AAP treatment 0.14 (−0.18 to 0.4
Data are presented as Spearman correlation coefficients (ρ) with 95-% confidence l
p-values. Abbreviations: ADMA Asymmetric dimethyl arginine, PANSS Positive and Ngenerated damage to DNA (8-oxodG), RNA (8-oxoGuo)
and lipids, neither in the individual groups nor in the
cohort as a whole. To our knowledge, this is the first
human study to assess the correlation between ADMA
and oxidative stress markers in vivo. It is not known which
tissues contribute the most to urinary and plasma markers
of oxidative stress (8-oxodG/8-oxoGuo and MDA, re-
spectively), and it may very well be that a subcellular inter-
action between ADMA and ROS in the endothelium does
not manifest itself on the systemic level.
There are some limitations that should be mentioned.
We did not include a population of patients who were
not treated with AAPs, and this limits our ability to
make conclusions on the relation between ADMA and
AAP treatment. Further, the study did not include an
alternative measure of endothelial dysfunction, such as
peripheral artery tonometry. Finally, the study was
cross-sectional, limiting the extent to which causal infer-
ences can be made. Hence, we are unable to control for
differences in i.e. smoking and diet, and although the
differences in these factors between patients and con-
trols would be expected to promote endothelial dysfunc-
tion and increased ADMA in patients, we cannot
exclude the possibility that they could have influenced
the results.hology, disease course and AAP use in schizophrenia
L-arginine:ADMA ratio
5) p = 0.31 0.13 (−0.19 to 0.42) p = 0.44
.28) p = 0.82 0.29 (−0.02 to 0.55) p = 0.07
.25) p = 0.70 0.32 (0.00 to 0.57) p = 0.05
6) p = 0.30) 0.004 (−0.31 to 0.32) p = 0.98
3) p = 0.40 −0.16 (−0.45 to 0.16) p = 0.32
imits (Fisher’s z-transformation with normal approximation) and corresponding
egative Syndrome Scale, AAP Atypical antipsychotics.
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In conclusion, plasma ADMA and the L-arginine:ADMA
ratio are not increased outside clinically relevant ranges
by schizophrenia and treatment with AAP. Further, we
found no evidence that ADMA or the L-arginine:ADMA
ratio is associated to markers of systemic DNA, RNA
and lipid damage from oxidation. The study contradicts
previous studies on plasma ADMA in schizophrenia
patients, and to our knowledge is the first human study
to assess the relation between ADMA and markers of
oxidative stress in vivo.
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